tetano
Editor, Senior Moderator
Respir Investig
. 2021 Jun 19;S2212-5345(21)00111-8.
doi: 10.1016/j.resinv.2021.06.003. Online ahead of print.
Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
Takehiro Izumo[SUP] 1 [/SUP], Naoyuki Kuse[SUP] 2 [/SUP], Nobuyasu Awano[SUP] 2 [/SUP], Mari Tone[SUP] 2 [/SUP], Keita Sakamoto[SUP] 2 [/SUP], Kohei Takada[SUP] 2 [/SUP], Yutaka Muto[SUP] 2 [/SUP], Kazushi Fujimoto[SUP] 2 [/SUP], Ayae Saiki[SUP] 2 [/SUP], Yu Ito[SUP] 2 [/SUP], Haruko Matsumoto[SUP] 2 [/SUP], Minoru Inomata[SUP] 2 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease (COVID-19) has afflicted large populations worldwide. Although vaccines aroused great expectations, their side effects on Japanese people and the antibody titer transition after vaccination are unclear.
Methods: The side effects of the BNT162b2 mRNA COVID-19 vaccine in participants who received vaccination at our center were investigated. Some participants were also surveyed for the antibody titer transition.
Results: In this study, 983 and 798 Japanese participants responded to the first and second doses, respectively. Side effects occurred in 757 (77.0%) and 715 participants (90.0%) after the first and second doses, respectively. No Grade 4 side effects occurred. The second dose had significantly more side effects than the first dose (p < 0.001). Side effects occurred after the second dose in 571 female (92.1%) and 178 male participants (80.1%). Female participants had a higher incidence of side effects than the male participants (p < 0.001). A comparison among the age groups showed significant differences (p = 0.018), and the frequency of side effects decreased with age. Twenty-three individuals participated in the survey of antibody titer transition. After the second vaccine dose, the median antibody titers for IgG and IgM were 3.76 and 0.07 AU/mL, respectively. Both IgG and IgM titers showed a significant increase over the study period (p < 0.001).
Conclusions: The BNT162b2 mRNA COVID-19 vaccine might be safe for Japanese people, and the antibody titer increased with two doses of vaccination. Larger nationwide studies are warranted to verify these findings.
Keywords: Antibody titer; Coronavirus disease; IgG/IgM antibody; Side effect; Vaccine.
. 2021 Jun 19;S2212-5345(21)00111-8.
doi: 10.1016/j.resinv.2021.06.003. Online ahead of print.
Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan
Takehiro Izumo[SUP] 1 [/SUP], Naoyuki Kuse[SUP] 2 [/SUP], Nobuyasu Awano[SUP] 2 [/SUP], Mari Tone[SUP] 2 [/SUP], Keita Sakamoto[SUP] 2 [/SUP], Kohei Takada[SUP] 2 [/SUP], Yutaka Muto[SUP] 2 [/SUP], Kazushi Fujimoto[SUP] 2 [/SUP], Ayae Saiki[SUP] 2 [/SUP], Yu Ito[SUP] 2 [/SUP], Haruko Matsumoto[SUP] 2 [/SUP], Minoru Inomata[SUP] 2 [/SUP]
Affiliations
- PMID: 34210623
- PMCID: PMC8214200
- DOI: 10.1016/j.resinv.2021.06.003
Abstract
Background: The coronavirus disease (COVID-19) has afflicted large populations worldwide. Although vaccines aroused great expectations, their side effects on Japanese people and the antibody titer transition after vaccination are unclear.
Methods: The side effects of the BNT162b2 mRNA COVID-19 vaccine in participants who received vaccination at our center were investigated. Some participants were also surveyed for the antibody titer transition.
Results: In this study, 983 and 798 Japanese participants responded to the first and second doses, respectively. Side effects occurred in 757 (77.0%) and 715 participants (90.0%) after the first and second doses, respectively. No Grade 4 side effects occurred. The second dose had significantly more side effects than the first dose (p < 0.001). Side effects occurred after the second dose in 571 female (92.1%) and 178 male participants (80.1%). Female participants had a higher incidence of side effects than the male participants (p < 0.001). A comparison among the age groups showed significant differences (p = 0.018), and the frequency of side effects decreased with age. Twenty-three individuals participated in the survey of antibody titer transition. After the second vaccine dose, the median antibody titers for IgG and IgM were 3.76 and 0.07 AU/mL, respectively. Both IgG and IgM titers showed a significant increase over the study period (p < 0.001).
Conclusions: The BNT162b2 mRNA COVID-19 vaccine might be safe for Japanese people, and the antibody titer increased with two doses of vaccination. Larger nationwide studies are warranted to verify these findings.
Keywords: Antibody titer; Coronavirus disease; IgG/IgM antibody; Side effect; Vaccine.